Gilead and Novo Nordisk sign trial collaboration for NASH combo therapy
Gilead Sciences Inc. and Novo Nordisk AS signed a trial agreement to study a triple combination therapy for nonalcoholic steatohepatitis (NASH).
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.